A New York City biotechnology startup is openly challenging one of the most firmly established ethical and legal boundaries in modern science: the prohibition on creating genetically modified human babies. Origin Genomics, led by founder and CEO Cathy Tie, is making the case that the potential medical benefits of editing disease-causing genes in human embryos now outweigh the risks that prompted a global moratorium on the practice.
The company recently gave NPR an exclusive tour of its laboratories, though Tie requested that the precise location be withheld for security reasons. Donning a white lab coat embroidered with her name and the company's logo, Tie guided an NPR reporter, photographer and videographer through the facility to demonstrate the technology her team is developing.
At the heart of the tour was a gray metal tank resembling an oversized thermos, sitting on the lab floor. Tie identified it as a cryogenic storage unit filled with liquid nitrogen, used to preserve the embryos central to the company's research. When she twisted open the black lid, white vapor from the liquid nitrogen curled outward. She then carefully withdrew a long metal rod holding frosted glass tubes at its tip.
Each tube, Tie explained, can hold as many as ten embryos, and the rod she displayed contained four of them. These frozen human embryos carry mutations responsible for serious diseases. They were donated by couples whose families have struggled for generations with life-threatening genetic disorders, giving the company a source of biological material for testing its gene-repair technology.
Origin's scientists extract stem cells from these donated embryos in order to evaluate how well their editing tools can correct the defective genes. The goal is to demonstrate that the benefits of repairing disease-causing mutations in embryos are substantial enough to justify revisiting current restrictions.
Under existing laws and international scientific consensus, creating a gene-edited baby is illegal in most countries, including the United States, where federal funding for such work on embryos is also restricted. The practice became widely taboo after a Chinese scientist, He Jiankui, announced in 2018 that he had created twin girls from embryos he had edited, an episode that drew near-universal condemnation from the scientific community and regulators worldwide.
That history explains the sensitivity surrounding Origin Genomics' ambitions. The company is not claiming it has created, or is about to create, a gene-edited baby. Instead, it is positioning itself as seeking to prove a scientific case: that editing genes linked to severe inherited disorders could prevent suffering in future children, and that the risks long cited as justification for a blanket ban may be manageable.
The ethical stakes are considerable. Critics of embryo editing worry about unintended consequences, including off-target genetic changes, mosaicism in which only some cells of an embryo are altered, and the fact that any modifications would be inherited by subsequent generations. They also warn of a slippery slope toward designer babies, in which editing is used for enhancement rather than medical necessity.
Supporters of research in this area, by contrast, argue that the technology has matured significantly since the He Jiankui scandal. They contend that a careful, regulated path toward clinical application could spare families from devastating genetic diseases that currently offer few or no treatment options. For couples who carry mutations for conditions that can be fatal in early childhood, embryo editing may represent a chance at a healthy biological child.
The embryos stored in Origin's cryogenic tank are not anonymous laboratory specimens. They came from families with direct experience of hereditary illness. A wife and husband who donated some of their embryos later told NPR about their hope of having healthy children with the help of gene editing, underscoring the deeply personal dimension of a debate that is often conducted in abstract terms.
Regulatory oversight remains a patchwork. While many nations have laws explicitly banning the implantation of genetically modified embryos, enforcement and research rules vary. Some countries permit limited laboratory research on edited embryos under strict conditions, provided the embryos are not allowed to develop beyond a certain stage or be transferred to a womb.
Origin Genomics appears to be operating in that research space, testing its technology on donated embryos rather than attempting a pregnancy. Still, the company's public argument — that it may be time to reconsider the prohibition on making gene-edited babies — places it squarely in the crosshairs of a debate that has divided scientists, ethicists, religious leaders and policymakers for years.
The broader question raised by the startup is how society should weigh hypothetical future harms against the concrete suffering of families today. As gene-editing tools such as CRISPR become more precise and more widely accessible, pressure is likely to build on regulators to define where the line should be drawn and who should draw it.
For now, Origin's work remains confined to its New York lab, where embryos carrying disease-causing mutations sit in liquid nitrogen, awaiting experiments designed to prove that their genetic defects can be repaired. Whether that research ultimately persuades the world to reconsider its ban is a question that will be answered not in a laboratory, but in courts, legislatures and the broader public square.
(0)